By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Tocagen Inc. 

3030 Bunker Hill Street
Suite 230
San Diego  California  92109  U.S.A.
Phone: 858-412-8400 Fax: 858-412-8499


Company News
San Diego's Tocagen Goes for $86 Million IPO 3/10/2017 7:44:20 AM
Tocagen Appoints Mark Foletta As Executive Vice President And Chief Financial Officer 3/7/2017 7:38:38 AM
Tocagen Receives Breakthrough Therapy Designation From FDA For Toca 511 & Toca FC In Recurrent High Grade Glioma 2/23/2017 6:40:54 AM
Tocagen Release: Company Expands Toca 5, Phase II/III Clinical Trial For Recurrent Brain Cancer, To South Korea 1/16/2017 7:17:31 AM
Tocagen Strengthens Leadership Team: Martin Duvall Appointed As Chief Executive Officer 11/2/2016 7:31:49 AM
Tocagen Presents Updated Tumor Response Data For Its Cancer-Selective Gene Therapy 10/5/2016 8:08:18 AM
Tocagen To Present Clinical And Preclinical Data At Two Scientific Meetings 9/30/2016 10:49:45 AM
First Patient Enrolled In Toca 6, Tocagen's Trial For Metastatic Cancers Evaluating Intravenously Delivered Toca 511 Virus 9/22/2016 8:12:47 AM
RiboMed Biotechnologies, Inc. And Tocagen Inc. Collaborate To Analyze Epigenetic Prognostic Markers, Including MGMT, In Recurrent Brain Tumors 7/6/2016 6:13:07 AM
Study Published In Science Translational Medicine Reports Favorable Safety And Extended Survival For Brain Cancer Patients Treated With Tocagen Inc.'s Cancer-Selective Viral Gene Therapy 6/2/2016 7:45:24 AM